New drug aims to ease lingering COVID symptoms
NCT ID NCT07123727
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tests the safety of a drug called NAI (Anktiva) in 40 adults aged 18-70 with long COVID—symptoms that persist after a COVID-19 infection. Researchers will monitor side effects and changes in lab results and vital signs over 30 days after treatment. The goal is to see if the drug is safe enough to study further for symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chan Soon-Schiong Institute for Medicine (CSSIFM)
RECRUITINGEl Segundo, California, 90245, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.